Charles River Laboratories International, Inc. (CRL)
USD 183.16
(-3.26%)
USD 183.16
(-3.26%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 4.53 Billion USD | -0.94% |
| 2022 | 4.57 Billion USD | 3.32% |
| 2021 | 4.43 Billion USD | 32.42% |
| 2020 | 3.34 Billion USD | 10.6% |
| 2019 | 3.02 Billion USD | 20.21% |
| 2018 | 2.51 Billion USD | 34.93% |
| 2017 | 1.86 Billion USD | 0.42% |
| 2016 | 1.85 Billion USD | 42.6% |
| 2015 | 1.3 Billion USD | 10.34% |
| 2014 | 1.18 Billion USD | 20.5% |
| 2013 | 979.96 Million USD | -0.32% |
| 2012 | 983.14 Million USD | -4.47% |
| 2011 | 1.02 Billion USD | -1.48% |
| 2010 | 1.04 Billion USD | 25.82% |
| 2009 | 830.26 Million USD | -13.56% |
| 2008 | 960.47 Million USD | 2.01% |
| 2007 | 941.57 Million USD | -1.21% |
| 2006 | 953.11 Million USD | 35.87% |
| 2005 | 701.47 Million USD | -38.71% |
| 2004 | 1.14 Billion USD | 252.43% |
| 2003 | 324.75 Million USD | -0.2% |
| 2002 | 325.4 Million USD | 21.03% |
| 2001 | 268.86 Million USD | -4.1% |
| 2000 | 280.35 Million USD | -40.72% |
| 1999 | 472.89 Million USD | 619.9% |
| 1998 | 65.68 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 4.44 Billion USD | -1.92% |
| 2024 Q2 | 4.17 Billion USD | -6.15% |
| 2023 Q2 | 4.47 Billion USD | -1.55% |
| 2023 FY | 4.53 Billion USD | -0.94% |
| 2023 Q3 | 4.25 Billion USD | -4.83% |
| 2023 Q1 | 4.54 Billion USD | -0.8% |
| 2023 Q4 | 4.53 Billion USD | 6.57% |
| 2022 Q3 | 4.71 Billion USD | -2.59% |
| 2022 Q1 | 4.4 Billion USD | -0.63% |
| 2022 FY | 4.57 Billion USD | 3.32% |
| 2022 Q4 | 4.57 Billion USD | -2.79% |
| 2022 Q2 | 4.83 Billion USD | 9.81% |
| 2021 Q2 | 4.36 Billion USD | 21.53% |
| 2021 Q4 | 4.43 Billion USD | -3.52% |
| 2021 FY | 4.43 Billion USD | 32.42% |
| 2021 Q1 | 3.59 Billion USD | 7.34% |
| 2021 Q3 | 4.59 Billion USD | 5.21% |
| 2020 Q4 | 3.34 Billion USD | 1.8% |
| 2020 Q1 | 3.52 Billion USD | 16.38% |
| 2020 Q3 | 3.28 Billion USD | -4.98% |
| 2020 Q2 | 3.46 Billion USD | -1.76% |
| 2020 FY | 3.34 Billion USD | 10.6% |
| 2019 Q3 | 3.01 Billion USD | -4.09% |
| 2019 Q2 | 3.14 Billion USD | 25.61% |
| 2019 FY | 3.02 Billion USD | 20.21% |
| 2019 Q4 | 3.02 Billion USD | 0.28% |
| 2019 Q1 | 2.5 Billion USD | -0.5% |
| 2018 Q1 | 1.84 Billion USD | -1.33% |
| 2018 Q3 | 2.52 Billion USD | -5.31% |
| 2018 Q4 | 2.51 Billion USD | -0.2% |
| 2018 FY | 2.51 Billion USD | 34.93% |
| 2018 Q2 | 2.66 Billion USD | 44.7% |
| 2017 Q2 | 1.79 Billion USD | -0.63% |
| 2017 Q4 | 1.86 Billion USD | 2.22% |
| 2017 FY | 1.86 Billion USD | 0.42% |
| 2017 Q1 | 1.8 Billion USD | -2.94% |
| 2017 Q3 | 1.82 Billion USD | 1.87% |
| 2016 Q2 | 1.9 Billion USD | 47.3% |
| 2016 FY | 1.85 Billion USD | 42.6% |
| 2016 Q3 | 1.8 Billion USD | -5.19% |
| 2016 Q4 | 1.85 Billion USD | 3.09% |
| 2016 Q1 | 1.29 Billion USD | -0.95% |
| 2015 Q1 | 1.15 Billion USD | -2.59% |
| 2015 FY | 1.3 Billion USD | 10.34% |
| 2015 Q4 | 1.3 Billion USD | 0.47% |
| 2015 Q3 | 1.29 Billion USD | 12.75% |
| 2015 Q2 | 1.15 Billion USD | -0.01% |
| 2014 Q1 | 931.5 Million USD | -4.95% |
| 2014 Q2 | 1.16 Billion USD | 25.05% |
| 2014 FY | 1.18 Billion USD | 20.5% |
| 2014 Q4 | 1.18 Billion USD | 3.22% |
| 2014 Q3 | 1.14 Billion USD | -1.79% |
| 2013 FY | 979.96 Million USD | -0.32% |
| 2013 Q3 | 969.73 Million USD | 1.1% |
| 2013 Q1 | 963.94 Million USD | -1.95% |
| 2013 Q2 | 959.2 Million USD | -0.49% |
| 2013 Q4 | 979.96 Million USD | 1.05% |
| 2012 Q2 | 981.22 Million USD | -1.96% |
| 2012 FY | 983.14 Million USD | -4.47% |
| 2012 Q1 | 1 Billion USD | -2.92% |
| 2012 Q4 | 983.14 Million USD | 1.6% |
| 2012 Q3 | 967.66 Million USD | -1.38% |
| 2011 Q2 | 1.11 Billion USD | -5.68% |
| 2011 Q4 | 1.03 Billion USD | -1.09% |
| 2011 FY | 1.02 Billion USD | -1.48% |
| 2011 Q1 | 1.18 Billion USD | 12.98% |
| 2011 Q3 | 1.04 Billion USD | -6.37% |
| 2010 Q2 | 762.62 Million USD | -5.05% |
| 2010 Q1 | 803.18 Million USD | -3.26% |
| 2010 FY | 1.04 Billion USD | 25.82% |
| 2010 Q4 | 1.04 Billion USD | 0.24% |
| 2010 Q3 | 1.04 Billion USD | 36.65% |
| 2009 Q1 | 869.55 Million USD | -9.47% |
| 2009 FY | 830.26 Million USD | -13.56% |
| 2009 Q4 | 830.26 Million USD | -1.44% |
| 2009 Q3 | 842.35 Million USD | -3.25% |
| 2009 Q2 | 870.66 Million USD | 0.13% |
| 2008 Q3 | 948.8 Million USD | 0.72% |
| 2008 Q1 | 931.22 Million USD | -1.1% |
| 2008 FY | 960.47 Million USD | 2.01% |
| 2008 Q4 | 960.47 Million USD | 1.23% |
| 2008 Q2 | 942.01 Million USD | 1.16% |
| 2007 Q4 | 941.57 Million USD | 1.22% |
| 2007 Q1 | 923.75 Million USD | -3.08% |
| 2007 FY | 941.57 Million USD | -1.21% |
| 2007 Q3 | 930.21 Million USD | -0.06% |
| 2007 Q2 | 930.79 Million USD | 0.76% |
| 2006 Q1 | 665.12 Million USD | -5.18% |
| 2006 FY | 953.11 Million USD | 35.87% |
| 2006 Q4 | 953.11 Million USD | 1.34% |
| 2006 Q3 | 940.54 Million USD | -2.76% |
| 2006 Q2 | 967.28 Million USD | 45.43% |
| 2005 FY | 701.47 Million USD | -38.71% |
| 2005 Q4 | 701.47 Million USD | -11.66% |
| 2005 Q3 | 794.1 Million USD | -1.61% |
| 2005 Q2 | 807.13 Million USD | -26.64% |
| 2005 Q1 | 1.1 Billion USD | -3.87% |
| 2004 FY | 1.14 Billion USD | 252.43% |
| 2004 Q4 | 1.14 Billion USD | 230.02% |
| 2004 Q3 | 346.81 Million USD | 3.89% |
| 2004 Q2 | 333.83 Million USD | 3.54% |
| 2004 Q1 | 322.43 Million USD | -0.71% |
| 2003 Q3 | 323.67 Million USD | 2.34% |
| 2003 Q4 | 324.75 Million USD | 0.33% |
| 2003 FY | 324.75 Million USD | -0.2% |
| 2003 Q2 | 316.28 Million USD | -0.26% |
| 2003 Q1 | 317.09 Million USD | -2.55% |
| 2002 Q1 | 363.84 Million USD | 35.33% |
| 2002 FY | 325.4 Million USD | 21.03% |
| 2002 Q4 | 325.4 Million USD | 6.16% |
| 2002 Q3 | 306.53 Million USD | -0.14% |
| 2002 Q2 | 306.95 Million USD | -15.63% |
| 2001 Q1 | 344.28 Million USD | 22.8% |
| 2001 Q2 | 296.12 Million USD | -13.99% |
| 2001 FY | 268.86 Million USD | -4.1% |
| 2001 Q3 | 294.41 Million USD | -0.58% |
| 2001 Q4 | 268.86 Million USD | -8.68% |
| 2000 Q3 | 282.4 Million USD | -42.73% |
| 2000 Q1 | 498.62 Million USD | 0.0% |
| 2000 Q2 | 493.09 Million USD | -1.11% |
| 2000 Q4 | 280.35 Million USD | -0.73% |
| 2000 FY | 280.35 Million USD | -40.72% |
| 1999 FY | 472.89 Million USD | 619.9% |
| 1998 FY | 65.68 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Agilent Technologies, Inc. | 4.91 Billion USD | 7.767% |
| Quest Diagnostics Incorporated | 7.6 Billion USD | 40.347% |
| Danaher Corporation | 30.99 Billion USD | 85.367% |
| Enzo Biochem, Inc. | 29.65 Million USD | -15197.461% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 77.947% |
| Laboratory Corporation of America Holdings | 8.83 Billion USD | 48.656% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | -29.397% |
| Qiagen N.V. | 2.3 Billion USD | -96.583% |
| Revvity, Inc. | 5.69 Billion USD | 20.308% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 91.257% |
| Waters Corporation | 3.47 Billion USD | -30.476% |